Indeed, monoclonal antibodies against IFN-I (Sifalimumab) and IFNAR1 (Anifrolumab), and inhibitors of Janus Kinases (Baricitinib, Tofacitinib), have shown promising results in clinical trials for SLE and type-I interferonopathies (284–286). Here, IFNAR1 is linked to systemic lupus erythematosus.